This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site



Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsLet’s ConnectStock Hub



About Sayana PressManaging ExpectationsSelf-administrationSupport & ResourcesVideosMaterials

Indicated for long term female contraception.  Click here for Sayana®-Press (medroxyprogesterone acetate) Prescribing Information.  Adverse event reporting information can be found at the bottom of the page.

Sayana®-Press: Injectable Female ContraceptiveAbout Sayana-Press

Prescribe women a LARC* injection convenient for their lifestyle and one which has been built on over 30 years of contraception heritage1. Sayana-Press is a smart device with a once-every-13-weeks administration schedule (+/-1 week) for eligible women.2

Learn MoreLoading

Explore Sayana-Press and watch the self-administration film.

Learn MoreLoading
Managing Expectations

What can women expect from Sayana-Press?

For a list of adverse events please refer to the SPC

Understand MoreLoading
Useful Resources

Order Materials

Sayana-Press Patient website

*Long acting reversible contraception
To read the full special warnings and precautions for use for Sayana-Press and see a full list of adverse events, refer to the Summary of Product Characteristics. The benefits of contraceptive options and their risks must be evaluated individually for each woman. If any of the conditions/risk factors mentioned is present, the benefits of Sayana-Press use should be weighed against the possible risks for each individual woman and discussed with the woman before she decides to start using it. In the event of aggravation, exacerbation or first appearance of any of these conditions or risk factors, the woman should contact her physician. The physician should then decide on whether Sayana-Press use should be discontinued.


Depo-Provera® Summary of Product Characteristics. Available at: Date accessed December 2020.Sayana-Press Summary of Product Characteristics. Available at: Date accessed December 2020.
PP-SAY-GBR-0187. February 2021

Adverse events should be reported. Reporting forms and information can be found at or search 

for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

Copyright © 2021 Pfizer Limited. All rights reserved.

VAT registration number GB201048427

PP-PFE-GBR-3849. November 2021

Add indication message here. It can link a link,
and you can EMBOLDEN text

This is an interstitial message to prompt a HCP before they login.

This can differ in its messaging based on a login being presented via a modal or via a page redirect.

Buttons for this interstitial are provided for confirming and declining this interstitial and can be configured via the traits.

For UK Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.​​​​​​

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021​​​​​​​

Yes No
You are now leaving PfizerPro  

​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

​​​​​​​Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​​​​​​​​
You are now leaving PfizerPro 
​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021